UNSPSC 51294518: Femoxetine hydrochloride

This classification denotes a serotonin agonist with the molecular formula C20H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2P1X5BE0XG, chemically known as piperidine, 3-((4-methoxyphenoxy)methyl)-1-methyl-4-phenyl-, (3r-trans)- but more generally known as femoxetine hydrochloride, which bears US NIH Compound Identifier 43103. European Medicines Agency schedules Femoxetine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02108MIG.

Most nations, for tariff and trade purposes, schedule femoxetine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, FEMOXETINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@@H]([C@H](C1)COC2CCC(CC2)OC)C3CCCCC3.CL.

UNSPSC 51294518 Femoxetine hydrochloride is a Commodity code that state and local procurement offices apply to pharmaceutical and chemical products, though recent solicitation activity under this code does not reflect the nominal product name. The single recent opportunity shows a county health authority procuring harm-reduction and emergency-response medical products—naloxone and drug deactivation systems—rather than the specific pharmaceutical compound the code nominates. The solicitation structure reflects typical state and local competitive bidding for recurring medical supply contracts, with fixed annual volumes, quarterly delivery cycles, standardized compliance requirements (E-Verify, drug-free workplace certification, insurance), and contract probation clauses.

Seminole County, Florida posted the only recent opportunity under this code—IFB 60459723LAS, issued June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through its Community Health Building in Sanford, Florida. The county required electronic bid submission through its e-procurement portal, with all shipping and delivery costs included in vendor pricing, and awarded the contract on a fixed-fee basis with an initial two-year term and one-year renewal option. The procurement flagged potential FEMA funding and associated federal compliance obligations. The mismatch between the code's nominal pharmaceutical scope and the actual medical supply being solicited suggests either a mis-tagging issue in the source data or a very narrow application of this Commodity code to state and local purchasing; geographic and issuing-body concentration cannot be assessed from a single opportunity.